New, Potent, and Selective Peptidic Oxytocin Receptor Agonists

详细信息    查看全文

• 作者：Kazimierz Wi艣niewski ; Sudarkodi Alagarsamy ; Robert Galyean ; Hiroe Tariga ; Dorain Thompson ; Brian Ly ; Halina Wi艣niewska ; Steve Qi ; Glenn Croston ; Regent Laporte ; Pierre J.-M. Rivi猫re ; Claudio D. Schteingart
• 刊名：Journal of Medicinal Chemistry
• 出版年：2014
• 出版时间：June 26, 2014
• 年：2014
• 卷：57
• 期：12
• 页码：5306-5317
• 全文大小：661K
• ISSN：1520-4804

文摘

Mothers of preterm babies frequently have difficulty establishing or maintaining lactation, thought to be due to interference with the milk ejection reflex. Administration of exogenous oxytocin can produce alveolar contraction and adequate breast emptying resulting in establishment of successful lactation. The natural hormone oxytocin is not receptor-selective and may cause hyponatremia via V₂ receptor mediated antidiuresis. We have designed a series of potent oxytocin analogues containing N-alkylglycines in position 7 with excellent selectivity versus the related V_1a, V_1b, and V₂ vasopressin receptors and short half-life: agonists 31 ([2-ThiMeGly⁷]dOT), 47 (carba-6-[Phe²,BuGly⁷]dOT), 55 (carba-6-[3-MeBzlGly⁷]dOT), and 57 (carba-1-[4-FBzlGly⁷]dOT) have EC₅₀ values at hOTR < 0.1 nM, selectivity ratios versus related human vasopressin receptors of >2000, IC₅₀ at hV_1aR > 500 nM, and total clearance in rats in the range of 60鈥?0 mL min^鈥? kg^鈥?. Compound 57 (FE 202767) is currently in clinical development for the treatment of preterm mothers requiring lactation support.